Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Springworks Therapeutics Inc (NQ: SWTX )

39.02 +2.72 (+7.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,413,118
Open 36.36
Bid (Size) 38.10 (3)
Ask (Size) 39.00 (27)
Prev. Close 36.30
Today's Range 36.24 - 39.61
52wk Range 20.19 - 53.92
Shares Outstanding 49,127,913
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+6.90%
+6.90%
1 Month
+36.39%
+36.39%
3 Month
-5.18%
-5.18%
6 Month
-7.93%
-7.93%
1 Year
+79.40%
+79.40%

More News

Read More
Earnings Scheduled For November 12, 2024
Via Benzinga
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
SWTX Stock Earnings: SpringWorks Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024
Via InvestorPlace
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
Via InvestorPlace
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.